Daniel Layish
YOU?
Author Swipe
View article: Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial Open
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-dai…
View article: Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection Open
ClinicalTrials.gov Identifier: NCT04666441.
View article: Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial Open
Background Emerging data suggests a possible role for cysteamine as an adjunct treatment for pulmonary exacerbations of cystic fibrosis (CF) that continue to be a major clinical challenge. There are no studies investigating the use of cyst…
View article: WS06-2 Initial results evaluating the add-on effect of the novel CFTR corrector PTI-801 in cystic fibrosis subjects
WS06-2 Initial results evaluating the add-on effect of the novel CFTR corrector PTI-801 in cystic fibrosis subjects Open
View article: WS12-6 Evaluating appropriate PROMs in CARE-CF-1 trial: Lynovex® (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacebations
WS12-6 Evaluating appropriate PROMs in CARE-CF-1 trial: Lynovex® (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacebations Open
View article: WS01.2 Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis
WS01.2 Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis Open
View article: WS13.2 Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects
WS13.2 Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects Open